<DOC>
	<DOCNO>NCT00255333</DOCNO>
	<brief_summary>The safety , tolerability pharmacokinetics INNO-105 , investigational anticancer drug , study patient solid tumor .</brief_summary>
	<brief_title>INNO-105 Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Have histologically cytologically confirm diagnosis solid malignancy ( patient may either measurable nonmeasurable disease ) . 2 . Be ≥18 year old . 3 . Not eligible effective therapy likely provide clinical benefit . 4 . Have Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤2 . 5 . Acceptable pretreatment clinical laboratory result . 6 . Life expectancy great 12 week . 1 . Have receive previous treatment INNO105 . 2 . Have active , uncontrolled systemic infection consider opportunistic , life threatening , clinically significant time treatment . 3 . Are pregnant lactating . 4 . Have psychiatric disorder ( ) would interfere consent , study participation , followup . 5 . Have receive chemotherapy , immunotherapy , vaccine , monoclonal antibody , major surgery , irradiation , whether conventional investigational , within 2 week treatment study . 6 . Have recover acute toxicity previous therapy prior enrollment . 7 . Have symptomatic untreated central nervous system ( CNS ) metastases . 8 . Have susceptibility hypotension , bradycardia , and/or hypopnea , patient know coronary heart disease , arrhythmia , cerebral vascular disease , chronic obstructive airway disease ( CO2retaining ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>